liquid biopsy

QIAGEN announced the early access launch of QIAsymphony Connect, its next-generation automated nucleic acid purification platform at AMP 2025, with full release expected in mid-2026. The new platform features enhanced speed, traceability, and connectivity for liquid biopsy applications. QIAGEN also showcased Sample to Insight workflows for comprehensive genomic profiling via a partnership with Element Biosciences and highlighted HRD assay development in collaboration with Myriad Genetics Inc., solidifying its focus on precision oncology.

ANGLE plc announced all resolutions were passed at its 2025 Annual General Meeting. The global leader in liquid biopsy technology, known for its Parsortix® PC1 System, focuses on circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company offers clinical services and diagnostic products, backed by over 100 peer-reviewed publications.